期刊
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY
卷 78, 期 -, 页码 290-298出版社
INT UNION CRYSTALLOGRAPHY
DOI: 10.1107/S2059798322000092
关键词
cereblon; immunomodulatory imide drugs; avadomide; iberdomide; ubiquitin ligases; protein degradation; crystal soaking
资金
- Max Planck Society
- Projekt DEAL
This study investigated the binding modes of next-generation IMiDs drugs on Cereblon using a crystal-soaking system, providing important insights for the development of future cereblon effectors.
Cereblon (CRBN) is the substrate receptor of the CRL4(CRBN) E3 ubiquitin ligase and is a central player in targeted protein degradation. It is the target of the thalidomide-derived immunomodulatory drugs (IMiDs) and is one of the most widely employed receptors for proteolysis-targeting chimeras (PROTAC5), both of which induce the ubiquitination and subsequent proteasomal degradation of target proteins. Structural studies of ligand binding to CRBN are crucial to elucidate the mechanisms of action and for mediation of side effects, ultimately aiding the development of next-generation IMiDs and PROTACs. With this aim, a crystal-soaking system based on the single-domain bacterial homologue MsCI4 has previously been established and used to delineate the binding modes of several classes of small molecules, including FDA-approved drugs, at the molecular level. Here, this system was used to characterize the binding of the next-generation IMiDs avadomide (CC-122) and iberdomide (CC-220) at high resolution, highlighting the advantages and limitations of the MsCI4 system and its implications for the development of future cereblon effectors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据